Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The expression of interleukin-1-receptor antagonist is reduced in pancreatic islets of patients with type 2 diabetes mellitus, and high glucose concentrations induce the production of interleukin-1beta in human pancreatic beta cells, leading to impaired insulin secretion, decreased cell proliferation, and apoptosis. METHODS: In this double-blind, parallel-group trial involving 70 patients with type 2 diabetes, we randomly assigned 34 patients to receive 100 mg of anakinra (a recombinant human interleukin-1-receptor antagonist) subcutaneously once daily for 13 weeks and 36 patients to receive placebo. At baseline and at 13 weeks, all patients underwent an oral glucose-tolerance test, followed by an intravenous bolus of 0.3 g of glucose per kilogram of body weight, 0.5 mg of glucagon, and 5 g of arginine. In addition, 35 patients underwent a hyperinsulinemic-euglycemic clamp study. The primary end point was a change in the level of glycated hemoglobin, and secondary end points were changes in beta-cell function, insulin sensitivity, and inflammatory markers. RESULTS: At 13 weeks, in the anakinra group, the glycated hemoglobin level was 0.46 percentage point lower than in the placebo group (P=0.03); C-peptide secretion was enhanced (P=0.05), and there were reductions in the ratio of proinsulin to insulin (P=0.005) and in levels of interleukin-6 (P<0.001) and C-reactive protein (P=0.002). Insulin resistance, insulin-regulated gene expression in skeletal muscle, serum adipokine levels, and the body-mass index were similar in the two study groups. Symptomatic hypoglycemia was not observed, and there were no apparent drug-related serious adverse events. CONCLUSIONS: The blockade of interleukin-1 with anakinra improved glycemia and beta-cell secretory function and reduced markers of systemic inflammation. (ClinicalTrials.gov number, NCT00303394 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, early interventions with insulin therapy in newly diagnosed T2D ( 83 ), with targeted anti-inflammatory therapy using an IL-1β antagonist ( 84 ), and with GLP-1 receptor agonists ( 85 ) have demonstrated that β-cell dysfunction can be reversed temporarily.”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [84]
In the citing paper
“improved glucose control required fewer glucose-lowering agents, including insulin”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [135]
In the citing paper
“a greater proportion of participants achieved a HbA1c <7%135”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [135]
In the citing paper
“A benefit for anakinra was also shown in a small, randomized trial of 70 patients with type 2 diabetes109.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [109]
In the citing paper
“However, the clinical study was still small and was not designed to determine optimal dosing, duration of use or long-term outcomes in disease control.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [109]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Biologic basis for interleukin-1 in disease.
Dinarello, C. (1996) · Blood · doi:10.1182/blood.v87.6.2095.bloodjournal8762095 · Cited by 4,344
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,114
Self-citationGlucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215318 · Cited by 1,005
Self-citationNeonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., Kim, H. J., Brewer, C., Zalewski, C., Wiggs, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055137 · Cited by 930
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2006) · Diabetes Care · doi:10.2337/diacare.29.s1.06.s43 · Cited by 924
Cited by
Inflammatory responses and inflammation-associated diseases in organs
Chen, L., Deng, H., Cui, H., Fang, J., Zuo, Z., Deng, J., Li, Y., Wang, X., & Zhao, L. (2018) · Oncotarget · doi:10.18632/oncotarget.23208 · Cited by 5,143
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
Inflammatory Mechanisms in Obesity
Gregor, M. F., & Hotamisligil, G. S. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101322 · Cited by 3,754
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737
“Most pro-inflammatory factors that are present at high levels in the blood of patients with T2D are IL-1 dependent, and blocking IL-1 activity has been shown to reduce their concentration”
BackgroundSelf-citationImmunological and inflammatory functions of the interleukin-1 family
Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466
Inflammasomes: mechanism of action, role in disease, and therapeutics
Guo, H., Callaway, J. B., & Ting, J. P.-Y. (2015) · Nature Medicine · doi:10.1038/nm.3893 · Cited by 3,340
Sterile inflammation: sensing and reacting to damage
Chen, G. Y., & Nuñez, G. (2010) · Nature Reviews Immunology · doi:10.1038/nri2873 · Cited by 3,051
Macrophages, inflammation, and insulin resistance
Olefsky, J. M., & Glass, C. K. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135846 · Cited by 2,733
Thioredoxin-interacting protein links oxidative stress to inflammasome activation
Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010) · Nature Immunology · doi:10.1038/ni.1831 · Cited by 2,708
Caspase Functions in Cell Death and Disease
McIlwain, D. R., Berger, T., & Mak, T. W. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008656 · Cited by 2,594
The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
Vandanmagsar, B., Youm, Y.-H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., Ravussin, E., Stephens, J. M., & Dixit, V. D. (2011) · Nature Medicine · doi:10.1038/nm.2279 · Cited by 2,655
Mechanisms and Functions of Inflammasomes
Lamkanfi, M., & Dixit, V. M. (2014) · Cell · doi:10.1016/j.cell.2014.04.007 · Cited by 2,503
Inflammation, metaflammation and immunometabolic disorders
Hotamisligil, G. S. (2017) · Nature · doi:10.1038/nature21363 · Cited by 2,570
Inflammatory links between obesity and metabolic disease
Lumeng, C. N., & Saltiel, A. R. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57132 · Cited by 2,319
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248
Inflammasomes in health and disease
Strowig, T., Henao-Mejia, J., Elinav, E., & Flavell, R. (2012) · Nature · doi:10.1038/nature10759 · Cited by 2,230
Inflammation in obesity, diabetes, and related disorders
Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.013 · Cited by 2,066
Self-citationInflammation as a link between obesity, metabolic syndrome and type 2 diabetes
Esser, N., Legrand-Poels, S., Piette, J., Scheen, A. J., & Paquot, N. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.04.006 · Cited by 1,981
“[67] Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, et al.”
BackgroundNF-κB, Inflammation, and Metabolic Disease
Baker, R. G., Hayden, M. S., & Ghosh, S. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2010.12.008 · Cited by 1,952
Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription
Kobayashi, E. H., Suzuki, T., Funayama, R., Nagashima, T., Hayashi, M., Sekine, H., Tanaka, N., Moriguchi, T., Motohashi, H., Nakayama, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms11624 · Cited by 1,878
Metabolic reprogramming in macrophages and dendritic cells in innate immunity
Kelly, B., & O'Neill, L. A. (2015) · Cell Research · doi:10.1038/cr.2015.68 · Cited by 1,876
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Fatty acid–induced NLRP3-ASC inflammasome activation interferes with insulin signaling
Wen, H., Gris, D., Lei, Y., Jha, S., Zhang, L., Huang, M. T.-H., Brickey, W. J., & Ting, J. P.-Y. (2011) · Nature Immunology · doi:10.1038/ni.2022 · Cited by 1,698
The Inflammasome NLRs in Immunity, Inflammation, and Associated Diseases
Davis, B. K., Wen, H., & Ting, J. P.-Y. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101405 · Cited by 1,618
The cellular and signaling networks linking the immune system and metabolism in disease
Osborn, O., & Olefsky, J. M. (2012) · Nature Medicine · doi:10.1038/nm.2627 · Cited by 1,551
An Overview of Nrf2 Signaling Pathway and Its Role in Inflammation
Saha, S., Buttari, B., Panieri, E., Profumo, E., & Saso, L. (2020) · Molecules · doi:10.3390/molecules25225474 · Cited by 1,388
“Another report demonstrated that the improvement of insulin secretion and protection in type-2 diabetes was associated with the suppression of IL-1 and IL-1 receptor [157].”
BackgroundThe IL-1 family: regulators of immunity
Sims, J. E., & Smith, D. E. (2010) · Nature Reviews Immunology · doi:10.1038/nri2691 · Cited by 1,418
“Although not a subject of this Review, which focuses on the immunological actions of IL-1 family members, there is also excitement around the potential for IL-1 inhibition in treating type 2 diabetes, resulting from a new understanding of the role of IL-1 in controlling pancreatic islet β-cell proliferation and surviva”
BackgroundImpact of the gut microbiota on inflammation, obesity, and metabolic disease
Boulangé, C. L., Neves, A. L., Chilloux, J., Nicholson, J. K., & Dumas, M.-E. (2016) · Genome Medicine · doi:10.1186/s13073-016-0303-2 · Cited by 1,438
Risk Factors Contributing to Type 2 Diabetes and Recent Advances in the Treatment and Prevention
Wu, Y., Ding, Y., Tanaka, Y., & Zhang, W. (2014) · International Journal of Medical Sciences · doi:10.7150/ijms.10001 · Cited by 1,279
The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives
Tsalamandris, S., Antonopoulos, A. S., Oikonomou, E., Papamikroulis, G.-A., Vogiatzi, G., Papaioannou, S., Deftereos, S., & Tousoulis, D. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.33.1 · Cited by 1,381
Masters, S. L., Dunne, A., Subramanian, S. L., Hull, R. L., Tannahill, G. M., Sharp, F. A., Becker, C., Franchi, L., Yoshihara, E., Chen, Z., et al. (2010) · Nature Immunology · doi:10.1038/ni.1935 · Cited by 1,330
Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes
Zatterale, F., Longo, M., Naderi, J., Raciti, G. A., Desiderio, A., Miele, C., & Beguinot, F. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2019.01607 · Cited by 1,180
“A clearer reduction of HbA1c, comparing this to the previous study on T2D (Larsen et al., 2007), can be explained based on the theory that pathogenic mechanisms of T2D could be exaggerated in the context of RA.”
BackgroundResultThe NLRP3 Inflammasome: A Sensor for Metabolic Danger?
Schroder, K., Zhou, R., & Tschopp, J. (2010) · Science · doi:10.1126/science.1184003 · Cited by 1,134
Dietary factors and low-grade inflammation in relation to overweight and obesity
Calder, P. C., Ahluwalia, N., Brouns, F., Buetler, T., Clement, K., Cunningham, K., Esposito, K., Jönsson, L. S., Kolb, H., Lansink, M., et al. (2011) · British Journal of Nutrition · doi:10.1017/s0007114511005460 · Cited by 1,098
Anti-inflammatory Agents: Present and Future
Dinarello, C. A. (2010) · Cell · doi:10.1016/j.cell.2010.02.043 · Cited by 1,095
“, 2009) Type 2 Diabetes (Donath et al., 2009; Larsen et al., 2009; Larsen et al., 2007) Smoldering Multiple Myeloma (Lust et al.”
The intestinal microbiota fuelling metabolic inflammation
Tilg, H., Zmora, N., Adolph, T. E., & Elinav, E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0198-4 · Cited by 1,089
Horror Autoinflammaticus: The Molecular Pathophysiology of Autoinflammatory Disease
Masters, S. L., Simon, A., Aksentijevich, I., & Kastner, D. L. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141627 · Cited by 1,065
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
Metabolic Inflammation and Insulin Resistance in Obesity
Wu, H., & Ballantyne, C. M. (2020) · Circulation Research · doi:10.1161/circresaha.119.315896 · Cited by 1,059
Adipokines in health and disease
Fasshauer, M., & Blüher, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.014 · Cited by 1,050
The vagus nerve and the inflammatory reflex – linking immunity and metabolism
Pavlov, V. A., & Tracey, K. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.189 · Cited by 1,040
IL‐1, IL‐18, and IL‐33 families of cytokines
Arend, W. P., Palmer, G., & Gabay, C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00624.x · Cited by 912
Inflammasomes and Their Roles in Health and Disease
Lamkanfi, M., & Dixit, V. M. (2012) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-101011-155745 · Cited by 935
Oxidative stress in obesity: A critical component in human diseases
Marseglia, L., Manti, S., D’Angelo, G., Nicotera, A., Parisi, E., Di Rosa, G., Gitto, E., & Arrigo, T. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms16010378 · Cited by 933
Historical insights into cytokines
Dinarello, C. A. (2007) · European Journal of Immunology · doi:10.1002/eji.200737772 · Cited by 926
IL-1 pathways in inflammation and human diseases
Gabay, C., Lamacchia, C., & Palmer, G. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.4 · Cited by 897
“However, the most compelling evidence came from a clinical trial showing that anakinra treatment results in decreased glycated hemoglobin levels and increased insulin production in patients with type 2 diabetes”
BackgroundA guiding map for inflammation
Netea, M. G., Balkwill, F., Chonchol, M., Cominelli, F., Donath, M. Y., Giamarellos-Bourboulis, E. J., Golenbock, D., Gresnigt, M. S., Heneka, M. T., Hoffman, H. M., et al. (2017) · Nature Immunology · doi:10.1038/ni.3790 · Cited by 831
Self-citationIncreased Number of Islet-Associated Macrophages in Type 2 Diabetes
Ehses, J. A., Perren, A., Eppler, E., Ribaux, P., Pospisilik, J. A., Maor-Cahn, R., Gueripel, X., Ellingsgaard, H., Schneider, M. K. J., Biollaz, G., et al. (2007) · Diabetes · doi:10.2337/db06-1650 · Cited by 783
Self-citationRidker, P. M., Thuren, T., Zalewski, A., & Libby, P. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.06.012 · Cited by 799
A clinical perspective of IL‐1β as the gatekeeper of inflammation
Dinarello, C. A. (2011) · European Journal of Immunology · doi:10.1002/eji.201141550 · Cited by 775
Inflammatory mechanisms in the regulation of insulin resistance
Tilg, H., & Moschen, A. R. (2008) · Molecular Medicine · doi:10.2119/2007-00119.tilg · Cited by 779
Macrophages, Immunity, and Metabolic Disease
McNelis, J. C., & Olefsky, J. M. (2014) · Immunity · doi:10.1016/j.immuni.2014.05.010 · Cited by 720
Upregulated NLRP3 Inflammasome Activation in Patients With Type 2 Diabetes
Lee, H.-M., Kim, J.-J., Kim, H. J., Shong, M., Ku, B. J., & Jo, E.-K. (2013) · Diabetes · doi:10.2337/db12-0420 · Cited by 734
Gut Microbiota as a Trigger for Metabolic Inflammation in Obesity and Type 2 Diabetes
Scheithauer, T. P. M., Rampanelli, E., Nieuwdorp, M., Vallance, B. A., Verchere, C. B., van Raalte, D. H., & Herrema, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.571731 · Cited by 673
“Administration of an IL1 receptor antagonist improved glucose tolerance via improving beta-cell function and systemic inflammation in humans (15).”
BackgroundLee, B.-C., & Lee, J. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.05.017 · Cited by 695
Stienstra, R., Joosten, L. A. B., Koenen, T., van Tits, B., van Diepen, J. A., van den Berg, S. A. A., Rensen, P. C. N., Voshol, P. J., Fantuzzi, G., Hijmans, A., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.11.011 · Cited by 676
Oslowski, C. M., Hara, T., O'Sullivan-Murphy, B., Kanekura, K., Lu, S., Hara, M., Ishigaki, S., Zhu, L. J., Hayashi, E., Hui, S. T., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.07.005 · Cited by 675
Targeting inflammation in the treatment of type 2 diabetes: time to start
Donath, M. Y. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4275 · Cited by 690
Self-citationUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Targeting adipose tissue in the treatment of obesity-associated diabetes
Kusminski, C. M., Bickel, P. E., & Scherer, P. E. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.75 · Cited by 678
The link between depression and diabetes: the search for shared mechanisms
Moulton, C. D., Pickup, J. C., & Ismail, K. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00134-5 · Cited by 670
Regulation of metabolism by the innate immune system
Lackey, D. E., & Olefsky, J. M. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.189 · Cited by 667
The Origins and Drivers of Insulin Resistance
Johnson, A. M. F., & Olefsky, J. M. (2013) · Cell · doi:10.1016/j.cell.2013.01.041 · Cited by 643
Kim, H. Y., Lee, H. J., Chang, Y.-J., Pichavant, M., Shore, S. A., Fitzgerald, K. A., Iwakura, Y., Israel, E., Bolger, K., Faul, J., et al. (2014) · Nature Medicine · doi:10.1038/nm.3423 · Cited by 635
Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation
Marchio, P., Guerra-Ojeda, S., Vila, J. M., Aldasoro, M., Victor, V. M., & Mauricio, M. D. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8563845 · Cited by 621
The role of interleukin-1 in general pathology
Kaneko, N., Kurata, M., Yamamoto, T., Morikawa, S., & Masumoto, J. (2019) · Inflammation and Regeneration · doi:10.1186/s41232-019-0101-5 · Cited by 617
“During ischemic disease, such as MI or cerebral infarction, or tissue injury, cell death by necrosis takes place and the IL-1α precursor is released in sterile inflammation [208] .”
BackgroundThe inflammation highway: metabolism accelerates inflammatory traffic in obesity
Johnson, A. R., Justin Milner, J., & Makowski, L. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01151.x · Cited by 603
Dendritic cells and cytokines in human inflammatory and autoimmune diseases
BLANCO, P., PALUCKA, A., PASCUAL, V, & BANCHEREAU, J. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.10.004 · Cited by 566
“IL-1RA has also shown therapeutic efficacy in gout [78], type II diabetes [79] as well as a series of hereditary diseases causing periodic inflammatory symptoms and grouped under the term ‘‘familial autoinflammatory syndromes’’ [80].”
BackgroundAnti-inflammatory therapies for cardiovascular disease
Ridker, P. M., & Luscher, T. F. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu203 · Cited by 550
Treating inflammation by blocking interleukin-1 in humans
Dinarello, C. A., & van der Meer, J. W. M. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.008 · Cited by 549
McArdle, M. A., Finucane, O. M., Connaughton, R. M., McMorrow, A. M., & Roche, H. M. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00052 · Cited by 532
Immunometabolism: an emerging frontier
Mathis, D., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2922 · Cited by 515
Saturated Fatty Acid and TLR Signaling Link β Cell Dysfunction and Islet Inflammation
Eguchi, K., Manabe, I., Oishi-Tanaka, Y., Ohsugi, M., Kono, N., Ogata, F., Yagi, N., Ohto, U., Kimoto, M., Miyake, K., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.01.023 · Cited by 519
Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity
Tilg, H., Adolph, T. E., Dudek, M., & Knolle, P. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00501-9 · Cited by 507
Ridker, P. M., Howard, C. P., Walter, V., Everett, B., Libby, P., Hensen, J., & Thuren, T. (2012) · Circulation · doi:10.1161/circulationaha.112.122556 · Cited by 530
Adipose Tissue Macrophages Promote Myelopoiesis and Monocytosis in Obesity
Nagareddy, P. R., Kraakman, M., Masters, S. L., Stirzaker, R. A., Gorman, D. J., Grant, R. W., Dragoljevic, D., Hong, E. S., Abdel-Latif, A., Smyth, S. S., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.03.029 · Cited by 509
Autoinflammatory Disease Reloaded: A Clinical Perspective
Kastner, D. L., Aksentijevich, I., & Goldbach-Mansky, R. (2010) · Cell · doi:10.1016/j.cell.2010.03.002 · Cited by 487
Immune Regulation of Metabolic Homeostasis in Health and Disease
Brestoff, J. R., & Artis, D. (2015) · Cell · doi:10.1016/j.cell.2015.02.022 · Cited by 497
“Clinical trials employing biologic agents that inhibit IL-1 (anakinra, canakinumab) or TNF-a (infliximab) in patients with type 2 diabetes or metabolic syndrome have been shown to produce moderate or no improvements in glucose metabolism, as assessed by glycated hemoglobin levels or indices of insulin resistance (Lars…”
Obesity and Inflammation: Epidemiology, Risk Factors, and Markers of Inflammation
Rodríguez-Hernández, H., Simental-Mendía, L. E., Rodríguez-Ramírez, G., & Reyes-Romero, M. A. (2013) · International Journal of Endocrinology · doi:10.1155/2013/678159 · Cited by 481
Macrophage Polarization in Chronic Inflammatory Diseases: Killers or Builders?
Parisi, L., Gini, E., Baci, D., Tremolati, M., Fanuli, M., Bassani, B., Farronato, G., Bruno, A., & Mortara, L. (2018) · Journal of Immunology Research · doi:10.1155/2018/8917804 · Cited by 508
The Role of Cytokines in Sleep Regulation
Krueger, J. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208786549281 · Cited by 507
Rossol, M., Pierer, M., Raulien, N., Quandt, D., Meusch, U., Rothe, K., Schubert, K., Schöneberg, T., Schaefer, M., Krügel, U., et al. (2012) · Nature Communications · doi:10.1038/ncomms2339 · Cited by 491
Immunological complications of obesity
Kanneganti, T.-D., & Dixit, V. D. (2012) · Nature Immunology · doi:10.1038/ni.2343 · Cited by 478
Ertunc, M. E., & Hotamisligil, G. S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r066514 · Cited by 488
Adipocyte dysfunction, inflammation and metabolic syndrome
Klöting, N., & Blüher, M. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9301-0 · Cited by 472
Mirza, R. E., Fang, M. M., Ennis, W. J., & Koh, T. J. (2013) · Diabetes · doi:10.2337/db12-1450 · Cited by 444
A role for the NLRP3 inflammasome in metabolic diseases—did Warburg miss inflammation?
Wen, H., Ting, J. P.-Y., & O'Neill, L. A. J. (2012) · Nature Immunology · doi:10.1038/ni.2228 · Cited by 457
Contribution of Adipose Tissue Inflammation to the Development of Type 2 Diabetes Mellitus
Burhans, M. S., Hagman, D. K., Kuzma, J. N., Schmidt, K. A., & Kratz, M. (2018) · Comprehensive Physiology · doi:10.1002/cphy.c170040 · Cited by 373
β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C. (2014) · Diabetes Care · doi:10.2337/dc14-0396 · Cited by 460
Emerging inflammasome effector mechanisms
Lamkanfi, M. (2011) · Nature Reviews Immunology · doi:10.1038/nri2936 · Cited by 434
Endoplasmic Reticulum Stress and Inflammation in Obesity and Diabetes
Hummasti, S., & Hotamisligil, G. S. (2010) · Circulation Research · doi:10.1161/circresaha.110.225698 · Cited by 436
Adipose tissue dysfunction contributes to obesity related metabolic diseases
Blüher, M. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.02.005 · Cited by 408
The NLRP3 inflammasome: Mechanism of action, role in disease and therapies
Wang, L., & Hauenstein, A. V. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100889 · Cited by 426
NLRP3 inflammasomes link inflammation and metabolic disease
De Nardo, D., & Latz, E. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.05.004 · Cited by 425
Herold, K. C., Gitelman, S. E., Ehlers, M. R., Gottlieb, P. A., Greenbaum, C. J., Hagopian, W., Boyle, K. D., Keyes-Elstein, L., Aggarwal, S., Phippard, D., et al. (2013) · Diabetes · doi:10.2337/db13-0345 · Cited by 411
Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy
Shahzad, K., Bock, F., Dong, W., Wang, H., Kopf, S., Kohli, S., Al-Dabet, M. M., Ranjan, S., Wolter, J., Wacker, C., et al. (2015) · Kidney International · doi:10.1038/ki.2014.271 · Cited by 411
Diabetic Cardiovascular Disease Induced by Oxidative Stress
Kayama, Y., Raaz, U., Jagger, A., Adam, M., Schellinger, I., Sakamoto, M., Suzuki, H., Toyama, K., Spin, J., & Tsao, P. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161025234 · Cited by 407
Targeting innate immune mediators in type 1 and type 2 diabetes
Donath, M. Y., Dinarello, C. A., & Mandrup-Poulsen, T. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0213-9 · Cited by 416
Self-citationBlüher, M., & Mantzoros, C. S. (2015) · Metabolism · doi:10.1016/j.metabol.2014.10.016 · Cited by 399
“For TNFα [91,92] or IL-1β [93] – which could also be considered as adipokines – inhibition of action has been already tested for different indications.”
BackgroundInfluential
Metadata
- Authors
- Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y.
- Affiliations
- University Hospital Zurich (CH)
- Steno Diabetes Centers (DK)
- University of Zurich (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-04-12
- Volume
- 356
- Issue
- 15
- Pages
- 1517-1526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2024378513
- Cited by
- 1,798
- References
- 29
- Citations by year
- 2026: 41 · 2025: 47 · 2024: 61 · 2023: 75 · 2022: 89 · 2021: 97 · 2020: 84 · 2019: 83 · 2018: 87 · 2017: 77 · 2016: 111 · 2015: 113 · 2014: 135 · 2013: 141 · 2012: 132
- FWCI
- 93.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- anakinra, interleukin-1 receptor antagonist, type 2 diabetes, IL-1β, beta-cell function, insulin secretion, HbA1c, systemic inflammation, interleukin-6, C-reactive protein, C-peptide, hyperinsulinemic-euglycemic clamp, insulin resistance, adipokines
- MeSH terms
- Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Blood Glucose, C-Reactive Protein, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Gene Expression Regulation, Glucose Tolerance Test, Heat-Shock Proteins, Glycated Hemoglobin, Humans, Insulin Resistance, Male, Middle Aged, Recombinant Proteins, RNA, Messenger, Transcription Factors, Interleukin-6, Body Mass Index, Receptors, Interleukin-1, Insulin-Secreting Cells, Glucose Transporter Type 4, Interleukin 1 Receptor Antagonist Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.